We then analyzed the levels of CLSTN1 isoforms using the TCGA breast cancer patient RNA-sequencing data, and found that higher fractions of CLSTN1-L, represented by high PSI values, were associated with higher levels of the mesenchymal marker vimentin in patient breast tumors, especially in luminal breast cancer (Fig. 7f and Supplementary Fig. 7c), These CLSTN1-L high patients also showed worse survival compared with those patients with lower levels of CLSTN1-L (Fig. 7g). The gene discussed is VIM; the disease is breast cancer.